GSK to pay $300M to license drug it sees as potential lupus treatment

GSK to pay $300M to license drug it sees as potential lupus treatment

Source: 
BioPharma Dive
snippet: 

The pharma believes a bispecific antibody developed by China’s Chimagen Biosciences could deplete the malfunctioning B cells that are behind autoimmune diseases like lupus.